21:57 Beijing time on August 1st, 2019Anthera Pharmaceutical(ANTH.us) the stock fluctuated and the share price plummeted 16.67%. As of press time, the stock was trading at US $0.040 per share, with a turnover of 4466 shares, a turnover rate of 0.02% and an amplitude of 19.79%.

The latest 2018-03-31 data show that the stock achieved operating income of $0.00, net profit of-7.72 million US dollars, earnings per share of-0.42 US dollars, gross profit of 161000.00 US dollars, and price-earnings ratio of 0.03 times.

In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.

Anthera Pharmaceuticals shares in the biotechnology industry, the overall increase of 1.11%. Among its related stocks, Vanda Pharmaceuticals Inc,AVEO Pharmaceutical Co., Regulus Therapeutics Inc rose a lot, Can Fite Biofarma Ltd, Delmar Pharmaceuticals Inc and Sellas Life Sciences Group Inc were more active, and the turnover rates were 34.38%, 5.43% and 4.52%, respectively. The related stocks with larger amplitudes were Can Fite Biofarma Ltd, Nanostring Technologies Inc and Aileron Therapeutics Inc, with amplitudes of 20.70%, 19.72% and 19.50%, respectively.

Anthera Pharmaceutical Co., Ltd.: Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )